What is Biotia?
Biotia operates within the critical sector of infectious disease diagnostics, employing cutting-edge genomics and artificial intelligence to identify and combat pathogens. The company's product suite, including BIOTIA-DX for precise microorganism identification and the BIOTIA-ID line for common infections like those in urinary and joint tissues, serves a diverse clientele encompassing researchers, clinicians, and patients. Strategic collaborations with esteemed institutions such as the Mayo Clinic and the Rockefeller Foundation highlight Biotia's commitment to advancing diagnostic capabilities through modern sequencing technologies and its ambition to globally improve health surveillance and the management of infectious disease outbreaks.
How much funding has Biotia raised?
Biotia has raised a total of $10.6M across 3 funding rounds:
Angel/Seed
$2.4M
Debt
$155K
Series A
$8M
Angel/Seed (2019): $2.4M with participation from Falcon III Ventures and Hyperplane Venture Capital
Debt (2021): $155K led by PPP
Series A (2022): $8M, investors not publicly disclosed
Key Investors in Biotia
PPP
Public-Private Partnership
Hyperplane Venture Capital
Hyperplane Venture Capital is a seed stage firm based in Boston, Massachusetts. The firm partners with exceptional founders who are harnessing machine intelligence, sensor technology, and cloud computing to design solutions at the nexus of perception, communication, and insight. Hyperplane's portfolio covers a wide array of industries including financial technologies, robotics, digital health, industrial automation, and others.
What's next for Biotia?
With the recent infusion of major strategic investment, Biotia is poised for accelerated growth and expanded market penetration. The company's focus on developing advanced diagnostic tools, supported by significant enterprise-level funding, positions it to further solidify its leadership in the genomics and AI-driven diagnostics space. Future endeavors will likely involve scaling operations, enhancing research and development for novel diagnostic solutions, and broadening its impact in addressing urgent global health challenges related to infectious diseases.
See full Biotia company page
